Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

Keywords

KRAS, Medicine, Lung cancer, Oncology, Genotyping

References

• Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations.孝至 大坪, 憲一 滝本 — 2011
• From Clinical Trials to Clinical Practice: Predictors of Response to Erlotinib in Advanced Non-Small Cell Lung Cancer Patients Pretreated with ChemotherapyFrancesca Mazzoni, Virginia Rotella, Nicola Pratesi — 2011
• Technology Assessment of Molecular Pathology Testing for the Estimation of Prognosis for Common CancersSreelatha Meleth, Katherine E. Reeder‐Hayes, Mahima Ashok — 2014
• A Genomics-Based Classification of Human Lung TumorsThe Clinical Lung Cancer Genome Project (CLCGP) and Network Genomic Medicine (NGM), — 2013
• ALK inhibitors and advanced non-small cell lung cancer (review).Antônio Rossi, Paolo Maione, Paola Claudia Sacco — 2014
• Distinct Clinical Course of EGFR-Mutant Resected Lung Cancers: Results of Testing of 1118 Surgical Specimens and Effects of Adjuvant Gefitinib and ErlotinibSandra P. D’Angelo, Yelena Y. Janjigian, Nicholas Ahye — 2012
• Clinical Significance of TTF-1 Protein Expression and TTF-1 Gene Amplification in Lung AdenocarcinomaJustine A. Barletta, Sven Perner, A. John Iafrate — 2008
• Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions.William Pao, Vincent A. Miller — 2005
• Diagnostic Value of Mutation-Specific Antibodies for Immunohistochemical Detection of Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer: A Meta-AnalysisZi Chen, Hongbing Liu, Chun-hua Yu — 2014
• KIF5B-RET fusions in lung adenocarcinomaTakashi Kohno, Hitoshi Ichikawa, Yasushi Totoki — 2012
• What's new in non-small cell lung cancer for pathologists: the importance of accurate subtyping, EGFR mutations and ALK rearrangements.Wendy A. Cooper, Sandra O’Toole, Michael Boyer — 2011
• VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528.Oliver Gautschi, Anne‐Marie C. Dingemans, Susanne Crowe — 2013
• VeriStrat® has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenibJG Kuiper, Joline S.W. Lind, Harry J.M. Groen — 2012
• Next-Generation Sequencing of Lung Cancer EGFR Exons 18-21 Allows Effective Molecular Diagnosis of Small Routine Samples (Cytology and Biopsy)Dario de Biase, Michela Visani, Umberto Malapelle — 2013
• Effective Use of PI3K and MEK Inhibitors to Treat Mutant K-Ras G12D and PIK3CA H1047R Murine Lung CancersJeffrey A. Engelman, Liang Chen, Xiaohong Tan — 2008
• Multi-Targeted Antiangiogenic Tyrosine Kinase Inhibitors in Advanced Non-Small Cell Lung Cancer: Meta-Analyses of 20 Randomized Controlled Trials and Subgroup AnalysesWenhua Liang, Xuan Wu, Shaodong Hong — 2014
• The introduction of systematic genomic testing for patients with non-small cell lung cancerStephanie Cardarella, Taylor M. Ortiz, Victoria A. Joshi — 2012
• Magnitude of the Benefit of Progression-Free Survival as a Potential Surrogate Marker in Phase 3 Trials Assessing Targeted Agents in Molecularly Selected Patients with Advanced Non-Small Cell Lung Cancer: Systematic ReviewKatsuyuki Hotta, Yuka Kato, Natasha B. Leighl — 2015
• Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsiesDoron Lipson, Marzia Capelletti, Roman Yelensky — 2012
• Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER).Fabrice André, Thomas Bachelot, Frédéric Commo — 2014

Cited by

• Promising Targets and Current Clinical Trials in Metastatic Non-Squamous NSCLCM.Asunción López — 2014
• The efficacy of crizotinib in patients with ALK-positive nonsmall cell lung cancerEric J. Balster, Waleed W. Smari, Frank A. Scarpino — 2015
• Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC).Adrien — 2015
• HER2 amplification and HER2 mutation are distinct molecular targets in lung cancersNicole Dubois — 2015
• Surrogate clinical endpoints to predict overall survival in non-small cell lung cancer trials-are we in a new era?員史 西川, 俊治 桑江, 隆行 秋山 — 2015
• Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practiceLouise Jottrand — 2016
• Resisting Resistance: Targeted Therapies in Lung CancerLinbo Lv, Liping Ren, Jia Xu — 2016
• The rise of genomic profiling in ovarian cancerJorge Dubatti — 2016
• Molecular biomarkers for lung adenocarcinomaTao Jiang — 2017
• Drinking Not Drowning: How to Deal With the Deluge of Potential Predictive Biomarker Approaches in Non-Small-Cell Lung Cancer.Brigitte Galliot — 2017
• Solitary pulmonary ground-glass opacity: is it time for new surgical guidelines?Juan Luis Hernández Álvarez, Roberto Velázquez Buendía — 2017
• Anti-tumor activity of osimertinib, an irreversible mutant-selective EGFR tyrosine kinase inhibitor, in NSCLC harboring EGFR Exon 20 InsertionsAscensión Rivas Hernández — 2018
• Clinical outcomes of patients with resected, early-stage ALK-positive lung cancerChristian Freres, José Antonio Sanahuja — 2018
• Beyond SNPs—genetics, genomics and other ‘omic approaches to ARDSNuala J. Meyer — 2014
• Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology.Donavan T. Cheng, Talia Mitchell, Ahmet Zehir — 2015
• Molekulardiagnostik des nichtkleinzelligen LungenkarzinomsArne Warth, Volker Endris, Mark Kriegsmann — 2015
• Targeting EGFR in lung cancer: Lessons learned and future perspectivesConor Steuer, Suresh S. Ramalingam — 2015
• Molecular Diagnostic Testing in Non-Small Cell Lung CancerJarushka Naidoo, Alexander Drilon — 2014
• Refining the treatment of NSCLC according to histological and molecular subtypesAnish Thomas, Stephen V. Liu, Deepa S. Subramaniam — 2015
• miRNA-197 and miRNA-184 are associated with brain metastasis in EGFR-mutant lung cancersJordi Remón, Daniel Álvarez-Berdugo, Margarita Majem — 2016

Related papers

• Assessing the significance of KRAS G12C mutation: Clinicopathologic features, treatments, and survival outcomes in a real-world KRAS mutant non-small cell lung cancer cohort.Wanyuan Cui, Fanny Franchini, Marliese Alexander — 2020
• 127P RAS, RAF and NF1 oncogenic mutations in KRAS-mutated lung adenocarcinomaDaniele Marinelli, Simona Pisegna, Antonella Chiavassa — 2022
• Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancerLuiz H. Araujo, Bianca Marmontel de Souza, Laura Hora Rios Leite — 2020
• Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancerLuiz H. Araujo, Bianca Mendes Souza, Laura Rabelo Leite — 2020
• KRAS gene amplification to define a distinct molecular subgroup of gastroesophageal adenocarcinoma.David Xu, Lindsay Alpert, Peng Xu — 2016
• KRAS gene amplification to define a distinct molecular subgroup of gastroesophageal adenocarcinoma.Les Henderson, Peng Xu, Emily O’Day — 2016
• Research progress of KRAS-targeted therapy for pancreatic ductal adenocarcinamaTongzheng Liu — 2018
• Targeting the KRAS Pathway in Non-Small Cell Lung Cancer.Pascale Tomasini, Preet Walia, Catherine Labbé — 2016
• Untangling the KRAS mutated lung cancer subsets and its therapeutic implicationsRitu Kulshrestha, Pawan Kumar, Amit Singh — 2021
• Research progress of molecular targeted therapy for lung cancerWeiyi Sun, Gang Chen — 2013